男友太凶猛1v1高h,大地资源在线资源免费观看 ,人妻少妇精品视频二区,极度sm残忍bdsm变态

Global EditionASIA 中文雙語Fran?ais
Business
Home / Business / Companies

EdiGene completes Series B financing round

By Liu Zhihua | chinadaily.com.cn | Updated: 2020-10-14 14:24
Share
Share - WeChat
A screenshot from EdiGene's official website. [Photo/edigene.com]

The Beijing-based EdiGene Inc, which develops genome editing technologies to accelerate drug discovery and develop novel therapeutics for a broad range of diseases, announced on Tuesday the successful completion of a 450 million yuan ($67 million) round of Series B financing.

Founded in 2015, EdiGene has established four gene editing based platforms and is advancing its early stage programs into clinical development for patients with genetic diseases and cancer.

The four platforms are ex vivo genome editing platforms for hematopoietic stem cells and T cells, in vivo therapeutic platform based on RNA base editing and high-throughput genome-editing screening to discover novel targeted therapies.

In addition, EdiGene has launched a Good Manufacturing Practice facility in 2018 in Guangdong province.

3H Health Investment led the round, and other new investors included Sequoia Capital China, Alwin Capital and Kunlun Capital, along with continued support by previous investors, including IDG Capital, Lilly Asia Venture, Huagai Capital and Green Pine Capital Partners.

Proceeds from the financing will be used to advance the company’s pipeline into clinics and expand the team, the company said.

Wang Minchuan, partner of 3H Health Investment, said as one of the most disruptive biomedical technologies, gene editing is rapidly moving toward clinics globally, and EdiGene is leading the wave in China.

Wang said his firm looks forward to contributing its clinical, business and policy resources to further strengthen the company’s capabilities, and is confident EdiGene is well-positioned to be a leader in gene editing therapeutics.

Wei Dong, CEO of EdiGene, said the financing enables the company to further scale up and transform its pipeline into the clinical stage.

Wei Wensheng, scientific founder of EdiGene, said together with the investors, the company looks forward to translating cutting-edge gene editing technologies into innovative therapies, bringing hope and health to patients and their families.

Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
CLOSE
 
主站蜘蛛池模板: 安康市| 武山县| 汶川县| 徐水县| 九龙城区| 霸州市| 鹰潭市| 珲春市| 汉阴县| 南平市| 望谟县| 海安县| 眉山市| 忻州市| 崇仁县| 边坝县| 方山县| 新乡市| 秦安县| 博客| 乐安县| 石渠县| 辽阳县| 翁源县| 开阳县| 库尔勒市| 吉林市| 沈阳市| 龙海市| 长寿区| 闽侯县| 宜昌市| 平江县| 云安县| 威远县| 雷山县| 平罗县| 八宿县| 内黄县| 龙游县| 马鞍山市|